quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 14, 2026

Wells Fargo & Company Q4 Earnings Call Highlights

View original at finance.yahoo.com
Wells Fargo & Company Q4 Earnings Call Highlights Wells Fargo & Company logo Key Points Wells Fargo reported strong 2025 results with $21.3 billion net income (EPS up 17%) and returned $23 billion to shareholders (13% dividend increase and $18 billion of buybacks), but expects buybacks to be lower in 2026 as it pursues…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • On potential credit card rate cap it is 'too early to know' what actions may be taken by policymakers

    80% confidence
  • Wells Fargo increased trading-related assets by 50% in 2025 to support customer trading flows and financing activities

    80% confidence
  • Share repurchases are expected to be lower in 2026 given opportunities for organic growth

    80% confidence
  • 2026 non-interest expense is forecast at approximately $55.7 billion

    80% confidence
  • The Fed's removal of the asset cap is 'a pivotal moment'

    80% confidence
  • 2025 results reflected 'significant momentum' across the company

    80% confidence
  • The increase in non-performing assets was borrower-specific and not indicative of systemic weakness

    80% confidence
  • Credit performance remained 'strong'

    80% confidence
  • Markets NII is expected to rise to approximately $2 billion in 2026

    80% confidence
  • Target CET1 range is approximately 10% to 10.5%

    80% confidence
  • 2026 total net interest income is expected to be approximately $50 billion, plus or minus

    80% confidence
  • Demand remains solid in several commercial real estate subsectors, while office valuations have stabilized

    80% confidence
  • Early vintages from newer credit card products are beginning to contribute to profitability after two to three years of upfront costs

    80% confidence
  • Wells Fargo's goal is to become a top-five U.S. investment bank

    80% confidence
  • Deal pipeline entering 2026 was 'meaningfully greater' than at any point in the last five years

    80% confidence
  • Average loans and average deposits expected to grow mid-single digits from Q4 2025 to Q4 2026

    80% confidence
  • Guidance assumes two to three Fed rate cuts in 2026 and relatively stable 10-year Treasury rates

    80% confidence
  • Period-end loans rose 5% from Q3, the strongest linked-quarter growth since Q1 2020

    80% confidence
  • Expects approximately $2.4 billion of gross expense reductions in 2026 from efficiency initiatives

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Wells Fargo & Company Q4 Earnings Call Highlights — Source | Via News | pt.VIA.NEWS